Lyell Immunopharma, Inc. is a T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company’s technologies are designed to generate T cells with the ability to persist and self renew while driving durable tumor cytotoxicity, even in the setting of an immunosuppressive tumor microenvironment. Its technologies can be applied in a target agnostic manner to multiple T cell modalities, including chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies. Its product candidates include LYL797, LYL845 and LYL119. The LYL119 is a ROR1 CAR T-cell product designed for enhanced cytotoxicity.